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Abstract
Background: We recently showed that women with four clinical phenotypes of polycystic ovary syndrome (PCOS)
do not demonstrate anatomical evidence of elevated prenatal androgen exposure as judged by a lower ratio of
the index (2D) to ring (4D) finger. However, those findings conflicted with a previous study where women with
PCOS had lower right hand 2D:4D compared to healthy female controls. Both these studies used Vernier calipers to
measure finger lengths - a method recently shown to be less reliable at obtaining finger length measurements
than computer-assisted analysis.
Methods: Ninety-six women diagnosed with PCOS according to the 2003 Rotterdam criteria had their finger
lengths measured with computer-assisted analysis. Participants were categorized into four recognized phenotypes
of PCOS and their 2D:4D compared to healthy female controls (n = 48) and men (n = 50).
Results: Digit ratios assessed by computer-assisted analysis in women with PCOS did not differ from female
controls, but were significantly lower in men. When subjects were stratified by PCOS phenotype, 2D:4D did not
differ among phenotypes or when compared to female controls.
Conclusion: Computer-assisted measurements validated that digit ratios of women with PCOS do not show
anatomical evidence of increased prenatal androgen exposure.
Background
Polycystic ovary syndrome (PCOS) is a complex endo-
crine disorder, having no single diagnostic trait [1,2].
Much controversy has surrounded the diagnosis of this
condition but in 2003 experts proposed that a diagnosis
of PCOS be based on the presence of two of three
symptoms: 1) oligo or chronic anovulation (amenor-
rhea), 2) biochemical and/or clinical hyperandrogenism
and 3) polycystic ovaries on ultrasonography [1,2].
These criteria recognized the broad clinical spectrum of
PCOS including, the manifestation four unique pheno-
types [3]. Frank PCOS represents the most severe form
of this condition and is characterized by the presence all
three symptoms. Non-PCO PCOS is characterized by
oligoanovulation, hyperandrogenism, but normal ovarian
morphology. Ovulatory PCOS describes the presence of
hyperandrogenism, polycystic ovaries and normal men-
strual cycles, whereas Mild PCOS describes the presence
of oligoamenorrhea and polycystic ovaries, but no
hyperandrogenism. While the validity of these pheno-
types is still being debated [4,5], there is consensus
among experts that PCOS imparts serious consequences
for the long-term health and quality of life of patients
and therefore should invite early identification and
intervention [1-6].
Despite familial clustering, the diverse manifestations of
PCOS make it challenging to determine a single etiologic
factor for this condition [7]. Experimental evidence in
nonhuman primates has suggested that programming
by prenatal androgens may contribute to variable
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heterogeneous clinical presentation (reviewed in [8]). Preg-
nant rhesus monkeys who received androgen treatment
early in pregnancy (i.e. Day 40-44 of a 165-day pregnancy)
gave arise to offspring that developed enlarged polycystic
ovaries, hyperandrogenism, oligo-anovulation, increased
basal luteinizing hormone (LH) secretion, insulin resis-
tance, abdominal obesity, and hyperlipidemia. By contrast,
the offspring of mothers that received treatment later
pregnancy (i.e. after Day 90) did not demonstrate the
same neuroendocrine alternations in LH secretion or
changes in insulin sensitivity (reviewed in [8]). The differ-
ential effects of androgens during fetal development indi-
cated that distinct programming windows existed for
androgens to permanently modify future aspects of repro-
ductive and metabolic function.
That prenatal androgens might contribute to develop-
ment of PCOS has been retrospectively investigated by
Cattrall et al. using a putative anatomical marker of in
utero androgen exposure [9 ] .E x p o s u r et oa n d r o g e n s
during fetal development affects finger length growth
and leads to distinct discrepancies in male and female
hand patterns (reviewed in [10]). Typically, men display
a lower ratio between the index (2D) and ring (4D) fin-
gers compared to women [11]. Cattrall et al. found a
small, yet significant, difference in the right hand 2D:4D
of women with PCOS compared to healthy female con-
trols (98.3% of that in the controls) providing support
for prenatal androgens in the etiology of PCOS [9].
More recently, we attempted to determine if clinical
phenotypes of PCOS were associated with variations in
2D:4D but found no such difference [12]. The popula-
tion studied by Cattrall et al. included only women with
the most severe forms of PCOS, while our study encom-
passed a more varied patient population [9,12]. Yet,
when the women participating in our study were strati-
fied by clinical phenotype, we failed to detect a differ-
ence in 2D:4D, even in women with Frank PCOS [12].
To date, studies investigating 2D:4D in women with
PCOS have used Vernier calipers to measure finger
lengths. Recent studies have indicated that use of Ver-
nier calipers is not the most reliable method of acquir-
ing 2D:4D [13-15]. Vernier calipers demonstrate an
interrater error of 1.2% or more [14], which has implica-
tions for comparing findings among studies [13]. Since
the difference in right 2D:4D detected by Cattrall et al.
may have fallen within the error range for Vernier cali-
pers, we feel it important to reevaluate 2D:4D in women
with PCOS using computer-based calipers which express
an interrater error of <1% [14]. To that end, the aim of
the current study was to re-evaluate the 2D:4D of our
previous PCOS study population using the more reliable
technique of computer-assisted analysis.
Methods
Study subjects
Women that had their finger lengths measured by Ver-
nier calipers as part of a previous study [12] were
invited to have their hands digitally scanned. Partici-
pants with PCOS had been recruited from women
responding to an ad because of concerns over PCOS
symptoms, as well as from those attending our Repro-
ductive Endocrinology or Gynecology practice at the
Royal University Hospital (Saskatoon, SK, Canada).
Female control subjects had been recruited from women
responding to an ad seeking healthy females of repro-
ductive age with regular menstrual cycles. Of the 98
women diagnosed with PCOS that were invited to parti-
cipate, 96 agreed to have their hands scanned at a fol-
low-up visit. Of the 51 female controls subjects, 48
agreed to have their hands scanned.
All female participants had been clinically assessed for
features of PCOS as previously described [12]. PCOS
was defined by the 2003 Rotterdam criteria as having
two of three symptoms: 1) oligo- or frank amenorrhea;
2) clinical and/or biochemical hyperandrogenism and 3)
sonographic evidence of polycystic ovaries [1,2]. Oligo-
amenorrhea was defined as an average cycle length of
>35 days [16]. Hyperandrogenism was defined by a hir-
sutism score ≥8 using the modified Ferriman-Gallwey
(FG) scale [17] and/or increased levels of serum andro-
gens measured by mass spectroscopy (Free Androgen
Index >10) [12]. Polycystic ovaries were defined as hav-
ing a mean total follicle count of both ovaries >22.5
b a s e do na ni n t e r n a lR O Ca n a l y s i sw h i c hs h o w e dt h i s
value to have 90.7% sensitivity and 83.3% specificity to
distinguish between normal and polycystic ovaries.
Fifty male participants were also recruited for this
study. Males were primarily students and staff from Uni-
versity of Saskatchewan, Royal University Hospital and
Cornell University. Males attested to being in good
health but no clinical information was gathered from
the male participants. Subjects with a history of injury
or illness affecting their hands or fingers were not eligi-
ble to participate.
Data collection
Participants were instructed to take off any jewelry or
rings that would obstruct finger length measurements.
The right and left hand of each participant was scanned
in grey-scale using a Hewlett Packard scanner (Hewlett-
Packard Company, Greeley, Colorado, USA). The volun-
teers gently positioned their hands on the surface of the
scanner with fingers two through five placed parallel to
one another and with their thumb directed outwards.
Hands were scanned at 100 dpi to ensure that measure-
ments were calibrated to a pixel per inch platform.
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ware (GNU Image Manipulation Program, version
2.6.4). The brightness/contrast of each image was subtly
modified on an individual basis to help visualize the tips
and proximal creases of the fingers as previously
described [13]. The lengths of the index and ring fingers
of each hand were then measured using mouse con-
trolled calipers. In each instance, calipers were posi-
tioned midline along the finger’s basal crease and
expanded to the edge of the finger tip. Finger length
measurements for all subjects were repeated one week
later in order to assess intra-observer reliability. Digit
ratios (2D:4D) for the left and right hands were com-
puted by dividing the measurement of the index finger
(2D) by that of the ring finger (4D). A two-way random
intra-class correlation coefficient (ICC) analysis [18] was
performed to assess intra-observer reliability using finger
length measurements made on the same images on two
separate occasions (i.e. one week apart). An ICC analysis
showed 0.910, 0.921 and 0.947 degree of reliability in
calculating left hand 2D:4D in women with PCOS,
female controls and men. The degree of reliability in
calculating right hand 2D:4D was 0.908, 0.910 and 0.928
in women with PCOS, female controls and men, respec-
tively. Digit ratios for the left and right hands reported
in this study denote the mean of the two measurements
that were taken one week apart.
Ethical considerations
This study was approved by the Biomedical Research
Ethics Review Board at the University of Saskatchewan.
All procedures conformed to the Canadian Tri-Council
Guidelines for Human Research and International Good
Clinical Practice Guidelines.
Statistics
Descriptive statistics (mean ± standard deviation) of the
2D:4D for the left and right hands were tabulated for all
women with PCOS, women with each clinical phenotype
of PCOS, female controls, and men. Mean (±SD) clini-
cal, hormonal and ultrasonographic characteristics of
female subjects were also calculated. A two-way mixed
ANOVA was performed to assess differences in 2D:4D
and clinical features among groups. Effect sizes for
2D:4D data were described by Cohen’s d. Linear regres-
sion analyses were used to examine associations between
2D:4D and clinical, hormonal and ultrasonographic fea-
tures of PCOS. A p-value < 0.050 was regarded as statis-
tically significant. Jmp 7 statistical software (SAS
Institute Inc., Cary, NC, USA) was used to perform the
statistical analysis.
Results
All PCOS vs. controls
Clinical features of all women meeting the criteria for
PCOS and female controls are summarized in Table 1.
Collectively, women with PCOS had higher BMI
(p < 0.0001), elevated hirsutism (modified FG) scores
(p < 0.0001), increased levels of total testosterone (p =
0.0048) and the free androgen index (p < 0.0001) com-
pared to female controls. Total follicle counts (p <
0.0001) and ovarian volume (p < 0.0001) were increased
in women with PCOS compared to female controls and
they also reported longer intervals between menstrual
cycles (p < 0.0001) compare to female controls.
Figure 1 compares mean 2D:4D of left and right hands
of all women with PCOS and both female and male
controls. Left 2D:4D were 0.982 ± 0.030, 0.974 ± 0.037,
and 0.949 ± 0.032, and right 2D:4D were 0.981 ± 0.028,
0.972 ± 0.028, and 0.949 ± 0.034, respectively. Left (p =
0.363) and right (p = 0.146) 2D:4D did not differ
between women with PCOS and female controls. By
contrast, left and right 2D:4D for men were significantly
lower than 2D:4D in women with PCOS (Left Hand, d
= -1.076; Right Hand, d = -1.252) and female controls
(Left Hand, d = -0.741; Right Hand, d = -0.918).
PCOS phenotypes vs. controls
Of the 96 women with PCOS, 63 were classified as hav-
ing Frank PCOS (66%), 4 as Non-PCO PCOS (4%), 19
as Ovulatory PCOS (20%) and 10 as Mild PCOS (10%).
Table 2 corroborates the designation of these pheno-
types by presenting the corresponding clinical, hormonal
and ultrasonographic data for participants in each of the
four phenotypes. Women with Frank PCOS had higher
hirsutism (modified FG) scores (p < 0.0001), increased
levels of testosterone (p = 0.022) and the free androgen
index (p < 0.0001), larger follicle counts (p < 0.0001)
and ovarian volume measurements (p < 0.0001) and
longer menstrual cycle lengths (p < 0.0001) compared to
female controls. Women with Non-PCO PCOS had
Table 1 A comparison of clinical features among women
with PCOS and female controls
PCOS
(n = 96)
Controls
(n = 48)
P-value
Age (y) 28.3 ± 4.5 26.9 ± 4.2 0.0684
BMI (kg/m
2) 32.2 ± 8.4 24.1 ± 3.7 <0.0001
Modified FG Score* 10.7 ± 6.6 3.3 ± 2.5 <0.0001
Total Testosterone (nmol/l) 3.6 ± 1.8 2.8 ± 0.9 0.0048
Free Androgen Index (%) 12.4 ± 9.4 5.7 ± 2.9 <0.0001
Total Follicle Count 41.1 ± 15.0 15.7 ± 5.5 <0.0001
Ovarian Volume (ml) 9.7 ± 3.2 6.1 ± 2.3 <0.0001
Menstrual Cycle Length (d) 109.0 ± 99.7 29.7 ± 3.0 <0.0001
* Modified Ferriman-Gallwey (FG) scale used to denote level of hirsutism.
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0.013) and longer menstrual cycles (p = 0.050) com-
pared to female controls but were similar in follicle
counts (p = 1.00) and ovarian volume (p = 0.955) mea-
surements compared to controls. Women with Ovula-
tory PCOS reported menstrual cycle lengths similar to
female controls (p = 1.00) but their hirsutism scores (p
< 0.0001), total follicle counts (p < 0.0001) and ovarian
volumes (p = 0.003) were higher than controls. Lastly,
women with Mild PCOS had longer menstrual cycles (p
= 0.014), higher follicle counts (p < 0.0001) and
increased ovarian volumes (p = 0.031) compared to
female controls but were similar in their indices of
hyperandrogenism compared to controls.
Mean left and right 2D:4D for each clinical phenotype
and the female controls are summarized in Table 2 and
presented in Figure 2. Left and right 2D:4D were similar
among clinical phenotypes of PCOS and female controls
(Comparisons for all pairs, p > 0.450). By contrast, male
2D:4D were significantly lower than 2D:4D in women
with Frank (Left Hand, d = 1.090, p < 0.0001; Right
Hand, d = -1.042, p < 0.0001), Ovulatory (Left Hand, d
= -1.118, p = 0.003; Right Hand, d = -1.259, p < 0.0001)
and Mild PCOS (Left Hand, d = -1.074, p = 0.031, Right
Hand, d = -1.156, p = 0.007) and female controls (Left
Hand, d =- 0 . 7 4 1 ,p=0 . 0 3 1 ,R i g h tH a n d ,d = -0.918, p
= 0.003).
Digit ratios and clinical features of PCOS
Associations between 2D:4D and signs and symptoms of
PCOS are summarized in Table 3. Digit ratios of the left
and right hands of female participants were not asso-
ciated with variations in BMI, length of the menstrual
cycle, total follicle counts or ovarian volume measure-
ments. By contrast, weak positive correlations were
detected between 2D:4D and measures of hyperandro-
genism including hirsutism scores (Left Hand, p =
0.017), total testosterone (Left Hand, p = 0.005; Right
Hand, p = 0.023) and the free androgen index (Left
Hand, p = 0.005; Right Hand, p = 0.021).
Discussion
The goal of this study was to address the controversy
over evidence of prenatal androgen exposure reflected
in the digit ratios of women with PCOS. Recently our
g r o u ps h o w e dt h a tw h e n2 D : 4 Dw e r em e a s u r e dw i t h
Vernier calipers, women with PCOS did not demon-
strate finger length patterns consistent with increased
levels of in utero androgen exposure [12]. This was in
contrast to a previous report that had also used Vernier
calipers to measure 2D:4D in women with PCOS [9].
Since observed differences in 2D:4D are generally small,
there is growing support that studies investigating
potential effects of prenatal androgens use the most
consistent and reliable technique available to measure
Table 2 A comparison of clinical features and mean digit ratios (2D:4D) among women with four clinical phenotypes
of PCOS and female controls
All PCOS
(n = 96)
Frank
(n = 63)
Non-PCO
(n = 4)
Ovulatory
(n = 19)
Mild
(n = 10)
Controls
(n = 48)
Age (y) 28.3 ± 4.5 27.8 ± 4.5
a 31.4 ± 4.4
a 29.3 ± 4.7
a 28.5 ± 3.9
a 26.9 ± 4.2
a
BMI (kg/m
2) 32.2 ± 8.4 33.5 ± 8.2
a 40.1 ± 5.3
a 31.4 ± 7.1
a 22.2 ± 4.6
b 24.1 ± 3.7
b
Modified FG Score* 10.7 ± 6.6 11.9 ± 7.0
a 12.0 ± 3.9
a 10.7 ± 3.8
a 2.3 ± 2.7
b 3.7 ± 2.9
b
Total Testosterone (nmol/l) 3.6 ± 1.8 3.8 ± 2.0
a 2.9 ± 1.7
a, b 2.7 ± 0.6
a, b 3.3 ± 1.2
a, b 2.8 ± 0.9
b
Free Androgen Index (%) 12.4 ± 9.4 15.3 ± 10.1
a 9.9 ± 3.7
a, b 6.8 ± 3.1
b 4.3 ± 1.8
b 5.7 ± 2.9
b
Total Follicle Count 41.1 ± 15.0 44.0 ± 15.1
a 15.6 ± 3.1
c 35.9 ± 10.4
b 44.3 ± 12.1
a, b 15.7 ± 5.5
c
Ovarian Volume (ml) 9.7 ± 3.2 10.1 ± 3.4
a 7.2 ± 3.0
a, b 9.1 ± 2.9
a 9.1 ± 2.1
a 6.1 ± 2.3
b
Menstrual Cycle Length (d) 109.0 ± 99.7 127.4 ± 98.3
a 75.5 ± 12.5
a 31.7 ± 4.7
b 101.1 ± 117.2
a 29.7 ± 3.0
b
Left Hand 2D:4D 0.982 ± 0.030 0.982 ± 0.029
a 0.981 ± 0.060
a 0.982 ± 0.028
a 0.983 ± 0.032
a 0.974 ± 0.037
a
Right Hand 2D:4D 0.981 ± 0.028 0.981 ± 0.029
a 0.965 ± 0.028
a 0.986 ± 0.027
a 0.983 ± 0.027
a 0.972 ± 0.028
a
Note: A column representing data for all women with PCOS has been added for ease of comparison. Within each row, assignment of the same letter represents
no significant difference between groups; *The modified Ferriman-Gallwey (FG) scale was used to denote level of hirsutism.
NS
NS
p<0.0001 p<0.0001
p<0.001 p<0.001
Left Hand Right Hand
PCOS
Female Controls
Men
2
D
:
4
D
1.04
1.02
1
0.98
0.96
0.94
0.92
0.9
Figure 1 Digit ratios of women with PCOS, female controls,
and men. Digit ratios did not differ between women with PCOS
and female controls (NS; not significant). Digit ratios in men were
lower than women with PCOS (p < 0.0001) and female controls (p
< 0.001). All data points represent Mean ± SD.
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Page 4 of 7finger lengths [13-15,18-20]. In this study, we imaged
the hands of women with four clinical phenotypes of
PCOS, healthy female controls and men, and used com-
puter-based calipers to measure their finger lengths
since this method was recently validated to be the most
reliable [14,15]. Consistent with this being the most reli-
able technique, we obtained levels of intra-observer
reliability when calculating 2D:4D (Mean ICC = 0.912)
that were much higher than what we obtained when we
used Vernier calipers to make measurements in this
same study population (Mean ICC = 0.845) [12]. These
levels of reliability were in range of what others have
demonstrated in studies comparing the appropriateness
of computer-assisted measurements for obtaining 2D:4D
in women [14].
I nt h ec u r r e n ts t u d y ,ac o m p a r i s o no f2 D : 4 Da m o n g
healthy female controls and women diagnosed with
PCOS by the Rotterdam criteria showed no significant
difference among groups. Unlike a previous report of
lower right-hand 2D:4D in women with PCOS [9], we
again noted a tendency toward lower 2D:4D in healthy
female controls which would contradict a theory sup-
porting excess prenatal androgen exposure in women
with clinically defined PCOS. A tendency for lower
2D:4D in female controls contributed to our paradoxical
finding that 2D:4D were positively, albeit weakly, asso-
ciated with clinical marke r so fa n d r o g e ne x c e s si n
women. Our female control subjects were carefully
selected following a complete clinical assessment for
PCOS and they showed no indications of androgen
excess, menstrual cycle irregularity or ovarian dysmor-
phology. The inclusion of men to our study population
afforded us the possibility to compare 2D:4D between
men and women with or without PCOS. This compari-
son substantiated that our female control group had
2D:4D that were consistent with what one would expect
when comparing 2D:4D among sexes [11]. Moreover,
our finding of lower 2D:4D in men compared to women
with PCOS further supported the notion that women
with PCOS do not demonstrate androgenized finger
lengths.
Since the PCOS criteria we used spanned a broad clin-
ical spectrum - with a potentially variable etiology - we
stratified subjects by phenotype and compared 2D:4D
among PCOS groups. Our hypothesis that variable man-
ifestations of PCOS might reflect variations in 2D:4D
was not supported even when using this more reliable
technique to obtain finger length measurements. That
is, even women with severe forms of the syndrome had
finger length patterns that were no different than milder
variants of PCOS or female controls. It is important to
acknowledge that the interpretation of these finding is
limited by the small number of subjects available for
analysis in each of the phenotypic groups. Comparisons
of 2D:4D among all women with PCOS and controls
were sufficiently powered in that they had greater than
80% power to detect a difference of 0.019 in 2D:4D at
an alpha level of 0.05 assuming a standard deviation of
0.035 [9,12]. By contrast, comparisons of 2D:4D in
women with Frank, Non-PCO, Mild or Ovulatory PCOS
all had less than 22% power to detect differences among
groups. Assuming the afore mentioned effect size and
standard deviation, a minimum of 55 subjects per group
would be required to perform an adequately powered
assessment of digit ratios among PCOS phenotypes.
There were several obstacles that limited our ability to
recruit the desired number of subjects. First, we were
limited in the number of women with PCOS that could
be identified in a small geographical area. The preva-
lence of PCOS is estimated at 5 - 10% [3] and while
that may appear to represent a relatively common con-
dition, our ability to locate women that were sufficiently
concerned over PCOS symptoms and willing to partici-
pate in a clinical study was limited. Second, the
Table 3 Associations between digit ratios (2D:4D) and
clinical features of PCOS
R Left 2D:4D P-value R Right 2D:4D P-value
BMI (kg/m
2) 0.144 0.092 0.102 0.231
Modified FG Score* 0.203 0.017 0.158 0.062
Total Testosterone
(nmol/l)
0.251 0.005 0.204 0.023
Free Androgen Index
(%)
0.256 0.005 0.208 0.021
Total Follicle Count 0.087 0.301 0.093 0.275
Ovarian Volume (ml) 0.097 0.255 0.097 0.253
Menstrual Cycle
Length (d)
0.033 0.703 -0.013 0.881
*Modified Ferriman-Gallwey (FG) scale used to denote level of hirsutism.
Left Hand Right Hand
FrankPCOS
2
D
:
4
D
1.05
1.03
1.01
0.99
0.97
0.95
0.93
0.91
NonͲPCOPCOS
OvulatoryPCOS
MildPCOS
FemaleControls
Men
a a
a a
a
a
a a
a,b
b
a,b
b
Figure 2 Digit ratios of women with four clinical phenotypes
of PCOS, female controls, and men. Digit ratios did not differ
between the various phenotypes of PCOS and female controls. Digit
ratios in men were lower than PCOS groups (p < 0.03) and female
controls (p < 0.01). All data points represent Mean ± SD.
Assignment of the same letter represents no significant difference
between groups.
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involved process requiring participation from various
clinical specialists. Difficulty in coordinating access to
resources limited the number of subjects we could
assess at any given time. Last, it may not have been
even possible to identify the necessary number of sub-
jects meeting the criteria for each PCOS phenotype.
This was likely the case for the Non-PCO PCOS group.
Diagnostic criteria for PCOS are controversial as are the
manifestation of these individual phenotypes [4,5]. Over
a two-year period, we screened over 125 women with
concerns of PCOS symptoms and only identified 4
women meeting the criteria for Non-PCO PCOS. At
this rate, it would have taken us over 25 years to iden-
tify the appropriate number of subjects. The low preva-
lence of this phenotype calls into question its validity
and the need to verify ultrasonographic criteria for poly-
cystic ovarian morphology [21-23].
There is growing concern that 2D:4D may represent
only a weak, or perhaps even useless, measure of prena-
tal androgen exposure [24-27]. It is difficult to know for
certain whether our negative findings represent a lack of
involvement of prenatal androgens in PCOS or whether
this represents a lack of an effect of androgen exposure
on 2D:4D per se. That prenatal androgens directly con-
tribute to the development of PCOS in humans seems
increasingly unlikely. Experimental evidence showing
that pregnant monkeys receiving exogenous androgens
gave rise to female offspring with PCOS symptoms is
the best data supporting a role for prenatal androgens
in PCOS [8]. However, very little is known about the
mechanism(s) whereby prenatal androgen excess leads
to PCOS-like alterations in reproductive and metabolic
function. In humans, it is unlikely that maternal andro-
gens sufficiently cross the placental barrier to affect the
fetus unless placental function is compromised in some
capacity in PCOS mothers [8]. Another possibility is a
fetal origin of androgen excess in which increased
androgen production from the fetal adrenals and/or
ovaries act during development to program future organ
systems [8]. There is no evidence to support either of
these possibilities and the most recent study of oppo-
site-sex twin pairs did not support an increased risk of
PCOS in the female twin despite exposure to intrauter-
ine androgens of the male fetus [28]. Given that our
study was limited by small sample sizes, it will be
important to revisit this issue with an adequately pow-
ered study using non-controversial criteria for PCOS - if
and when they come to fruition.
Conclusions
Computer-based measurements of 2D:4D verified that
women with clinical phenotypes of PCOS do not exhi-
bit anatomical indications of increased prenatal
androgen exposure. The current study also extends our
previous observations to show that 2D:4D in women
with PCOS were higher than those in men, consistent
with PCOS patients having relatively lower levels of in
utero androgen exposure. We caution that these
results do not entirely rule out the possibility that in
utero androgens play a role in the development of
PCOS; however, androgenized 2D:4D are not a charac-
teristic of PCOS.
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